Discover 49 paid clinical trials in Bakersfield, California. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 49
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
for
Asthma
Location: Bakersfield CA, Huntington Beach CA, Mission Viejo CA,
Sponsor: GlaxoSmithKline
Sex: All
Age: 12 - 17
Code: NCT05757102
Phase3, Recruiting
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
for
HIV Infections
Location: Bakersfield CA, West Hollywood CA, Palm Springs CA,
Sponsor: ViiV Healthcare
Sex: All
Age: 18+
Code: NCT07202546
Phase2, Recruiting
A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
for
Non-muscle-invasive Bladder Cancer
Location: Bakersfield CA, Downey CA, Murrieta CA, Mesa AZ,
Sponsor: SURGE Therapeutics
Sex: All
Age: 18+
Code: NCT05710848
Phase1, Phase2, Recruiting
Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt Disease
for
Stargardt Disease
Location: Bakersfield CA, Bellaire TX, Pittsburgh PA
Sponsor: Ray Therapeutics, Inc.
Sex: All
Age: 16+
Code: NCT07439887
Phase1, Phase2, Recruiting
Clinical Evaluation of Low Contrast Visual Performance and Low Light Phenomena in Patients With Various Intraocular Lens Implants
Get alerts for new trials in your area by subscribing now
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
for
Non-muscle Invasive Bladder Cancer
Location: Bakersfield CA, Orange CA, Phoenix AZ, Queen Creek AZ,
Sponsor: Protara Therapeutics
Sex: All
Age: 18+
Code: NCT05951179
Phase2, Recruiting
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
for
High-Risk Non-Muscle-Invasive Bladder Cancer
Location: Bakersfield CA, San Diego CA, Orange CA, Irvine CA,
Sponsor: CG Oncology, Inc.
Sex: All
Age: 18+
Code: NCT06567743
Phase2, Recruiting
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
for
Urinary Bladder Neoplasms,
Location: Bakersfield CA, Los Angeles CA, Torrance CA,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06833073
Phase2, Recruiting
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
for
Intermediate Risk Non-Muscle Invasive Bladder Cancer
Location: Bakersfield CA, Santa Monica CA, Los Angeles CA,
Sponsor: Ferring Pharmaceuticals
Sex: All
Age: 18+
Code: NCT06510374
Phase3, Recruiting
A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
for
Bladder Cancer, Urinary Bladder Neoplasms
Location: Bakersfield CA, Austin TX, Myrtle Beach SC,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT07222488
Phase1, Phase2, Recruiting
Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer
for
Bladder (Urothelial, Transitional Cell) Cancer,
Location: Bakersfield CA, Queen Creek AZ, Arlington TX,
Sponsor: Protara Therapeutics
Sex: All
Age: 18+
Code: NCT07480356
Phase3, Recruiting
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
Location: Bakersfield CA, Orange CA, Chandler AZ, Queen Creek AZ,
Sponsor: UroGen Pharma Ltd.
Sex: All
Age: 18+
Code: NCT06774131
Phase3, Recruiting
Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study
Location: Bakersfield CA, Santa Barbara CA, Austin TX,
Sponsor: Ocular Therapeutix, Inc.
Sex: All
Age: 50+
Code: NCT07516132
Phase3, Recruiting
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio
for
Geographic Atrophy Secondary to Age-related Macular Degeneration,
Location: Bakersfield CA, Oxnard CA, Encino CA, Torrance CA,
Sponsor: Apellis Pharmaceuticals, Inc.
Sex: All
Age: 60+
Code: NCT07215390
Phase2, Recruiting
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK
for
Macular Edema Secondary to Inflammation
Location: Bakersfield CA, Oxnard CA, Los Angeles CA, Glendale CA,
Sponsor: Kodiak Sciences Inc
Sex: All
Age: 18+
Code: NCT06990399
Phase3, Recruiting
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE
for
Macular Edema Secondary to Inflammation
Location: Bakersfield CA, Oxnard CA, Los Angeles CA, Glendale CA,
Sponsor: Kodiak Sciences Inc
Sex: All
Age: 18+
Code: NCT06996080
Phase3, Recruiting
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
for
Breast Cancer
Location: Bakersfield CA, Solvang CA, Los Angeles CA,
Sponsor: Stemline Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT06492616
Phase3, Recruiting
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
for
Colorectal Neoplasms
Location: Bakersfield CA, Glendale CA, Santa Monica CA,
Sponsor: Janssen Research & Development, LLC
Sex: All
Age: 18+
Code: NCT06662786
Phase3, Recruiting
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
for
Melanoma Stage IV, Solid Tumor
Location: Bakersfield CA, Los Angeles CA, Fullerton CA,
Sponsor: Georgiamune Inc
Sex: All
Age: 18+
Code: NCT06425926
Phase1, Phase2, Recruiting
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
for
Non-small Cell Lung Cancer
Location: Bakersfield CA, Beverly Hills CA, Billings MT,